Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

Bibliographic Details
Main Authors:	Gu, Shuyan, Mu, Yiming, Zhai, Suodi, Zeng, Yuhang, Zhen, Xuemei, Dong, Hengjin
Format:	Online
Language:	English
Published:	Public Library of Science 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091768/

Similar Items

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
by: Gu, Shuyan, et al.
Published: (2016)

Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis
by: Gu, Shuyan, et al.
Published: (2015)

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
by: Kaku, Kohei, et al.
Published: (2014)

Not so critical appraisal of dapagliflozin
by: Doggrell, Sheila A
Published: (2014)

On the potential of acarbose to reduce cardiovascular disease
by: Standl, Eberhard, et al.
Published: (2014)

Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients
by: He, Ke, et al.
Published: (2014)

Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study
by: Philip, Elizabeth, et al.
Published: (2013)

Dapagliflozin: BMS 512148; BMS-512148
Published: (2012)

A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy
by: Orme, Michelle, et al.
Published: (2014)

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice†
by: Tatarkiewicz, K, et al.
Published: (2014)

Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis
by: Peng Men, et al.
Published: (2018-09-01)

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment
by: van der Walt, J-S, et al.
Published: (2013)

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
by: Charokopou, M., et al.
Published: (2015)

Dapagliflozin-Induced Acute-on-Chronic Liver Injury
by: Levine, Joshua A., et al.
Published: (2016)

Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
by: Rosak, Christoph, et al.
Published: (2012)

Acarbose treatments improve arterial stiffness in patients with type 2 diabetes mellitus
by: Uzui, Hiroyasu, et al.
Published: (2011)

Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes
by: Sosale, Bhavana, et al.
Published: (2016)

Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
by: Chao, Edward C
Published: (2012)

Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
by: Imamura, Akira, et al.
Published: (2013)

Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
by: Salvo, Marissa C, et al.
Published: (2014)

Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis
by: Karun Badwal, et al.
Published: (2018-01-01)

Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
by: Daniele, Giuseppe, et al.
Published: (2016)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
by: Heerspink, H. J. L., et al.
Published: (2016)

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
by: Tamez, Hector E., et al.
Published: (2015)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
by: Kuecker, Catherine M, et al.
Published: (2016)

Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
by: Saeed, Mujahid A, et al.
Published: (2014)

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
by: Jones, G, et al.
Published: (2010)

Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema: A Meta-Analysis of Randomized Controlled Trials
by: Chen, Guohai, et al.
Published: (2014)

Factors impacting end-users' usage of ERP in China
by: Suodi, Zhang, et al.
Published: (2013)

A Case of Postprandial Hypotension in the Intensive Care Unit Treated With Acarbose
by: Choi, Joon Hyouk, et al.
Published: (2011)

The complete genome sequence of the acarbose producer Actinoplanes sp. SE50/110
by: Schwientek, Patrick, et al.
Published: (2012)

INFLUENCE OF ACARBOSE ON POSTPRANDIAL DYSMETABOLISM: RESULTS OF AN OPEN-LABEL RANDOMIZED STUDY
by: A. Ya. Cherniak, et al.
Published: (2013-01-01)

Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes
by: DiNicolantonio, James J, et al.
Published: (2015)

Influence of terpenoids and acarbose on glycosyltransferases produced by strain Leuconostoc mesenteroides URE 13
by: Bivolarski, Veselin, et al.
Published: (2014)

Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose
by: Chen, Po-Hsun, et al.
Published: (2014)

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
by: Rosenstock, Julio, et al.
Published: (2012)

Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study
by: Carlson, Glenn F., et al.
Published: (2011)

Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
by: Chang, Yoon-Kyung, et al.
Published: (2016)

Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
by: Chang, Yoon-Kyung, et al.
Published: (2016)

Impact of new rural cooperative medical scheme on the equity of health services in rural China
by: Jianhua Chen, et al.
Published: (2018-06-01)